Related Experiment Video
Updated: Aug 20, 2025

Tractable Mammalian Cell Infections with Protozoan-primed Bacteria
Published on: April 2, 2013
The Obligate Intracellular Bacterial Pathogen Anaplasma phagocytophilum Exploits Host Cell Multivesicular Body
Curtis B Read1, Mary Clark H Lind1, Travis J Chiarelli1
1Department of Microbiology and Immunology, Virginia Commonwealth University Medical Center, School of Medicine, Richmond, Virginia, USA.
Abstract:
Anaplasma phagocytophilum is the etiologic agent of the emerging infection, granulocytic anaplasmosis. This obligate intracellular bacterium lives in a host cell-derived vacuole that receives membrane traffic from multiple organelles to fuel its proliferation and from which it must ultimately exit to disseminate infection. Understanding of these essential pathogenic mechanisms has remained poor. Multivesicular bodies (MVBs) are late endosomal compartments that receive biomolecules from other organelles and encapsulate them into intralumenal vesicles (ILVs) using endosomal sorting complexes required for transport (ESCRT) machinery and ESCRT-independent machinery. Association of the ESCRT-independent protein, ALIX, directs MVBs to the plasma membrane where they release ILVs as exosomes. We report that the A. phagocytophilum vacuole (ApV) is acidified and enriched in lysobisphosphatidic acid, a lipid that is abundant in MVBs. ESCRT-0 and ESCRT-III components along with ALIX localize to the ApV membrane. siRNA-mediated inactivation of ESCRT-0 and ALIX together impairs A. phagocytophilum proliferation and infectious progeny production. RNA silencing of ESCRT-III, which regulates ILV scission, pronouncedly reduces ILV formation in ApVs and halts infection by arresting bacterial growth. Rab27a and its effector Munc13-4, which drive MVB trafficking to the plasma membrane and subsequent exosome release, localize to the ApV. Treatment with Nexinhib20, a small molecule inhibitor that specifically targets Rab27a to block MVB exocytosis, abrogates A. phagocytophilum infectious progeny release. Thus, A. phagocytophilum exploits MVB biogenesis and exosome release to benefit each major stage of its intracellular infection cycle: intravacuolar growth, conversion to the infectious form, and exit from the host cell. IMPORTANCE Anaplasma phagocytophilum causes granulocytic anaplasmosis, a globally emerging zoonosis that can be severe, even fatal, and for which antibiotic treatment options are limited. A. phagocytophilum lives in an endosomal-like compartment that interfaces with multiple organelles and from which it must ultimately exit to spread within the host. How the bacterium accomplishes these tasks is poorly understood. Multivesicular bodies (MVBs) are intermediates in the endolysosomal pathway that package biomolecular cargo from other organelles as intralumenal vesicles for release at the plasma membrane as exosomes. We discovered that A. phagocytophilum exploits MVB biogenesis and trafficking to benefit all aspects of its intracellular infection cycle: proliferation, conversion to its infectious form, and release of infectious progeny. The ability of a small molecule inhibitor of MVB exocytosis to impede A. phagocytophilum dissemination indicates the potential of this pathway as a novel host-directed therapeutic target for granulocytic anaplasmosis.
Insights
Anaplasma phagocytophilum hijacks host cell multivesicular bodies (MVBs) for growth and spread. Inhibiting MVB exocytosis blocks bacterial release, offering a potential therapeutic target for granulocytic anaplasmosis.
Area of Science:
- Microbiology
- Cell Biology
- Infectious Diseases
Background:
- Anaplasma phagocytophilum causes granulocytic anaplasmosis, a severe emerging zoonosis with limited treatment options.
- The bacterium resides in a host vacuole, requiring understanding of its intracellular proliferation and dissemination mechanisms.
- Multivesicular bodies (MVBs) are key endosomal compartments involved in cargo sorting and exosome release.
Purpose of the Study:
- To investigate the role of host cell MVB biogenesis and exosome release in the Anaplasma phagocytophilum infection cycle.
- To identify host factors exploited by A. phagocytophilum for intracellular survival and dissemination.
- To explore potential host-directed therapeutic strategies targeting MVB pathways.
Main Methods:
- Localization studies of ESCRT machinery, ALIX, Rab27a, and Munc13-4 to the Anaplasma phagocytophilum vacuole (ApV).
- siRNA-mediated gene silencing to assess the impact of ESCRT-0, ESCRT-III, and ALIX on bacterial proliferation.
- Treatment with Nexinhib20, a Rab27a inhibitor, to evaluate effects on infectious progeny release.
Main Results:
- The ApV shares characteristics with MVBs, including acidification and enrichment of lysobisphosphatidic acid.
- ESCRT components (ESCRT-0, ESCRT-III) and ALIX localize to the ApV, and their inactivation impairs bacterial growth and progeny production.
- Rab27a and Munc13-4 are present at the ApV, and inhibition of Rab27a blocks infectious progeny release.
Conclusions:
- Anaplasma phagocytophilum utilizes host MVB biogenesis and exosome release pathways for intracellular growth, differentiation, and dissemination.
- The ApV interfaces with host endosomal trafficking machinery, including ESCRT and Rab27a-dependent pathways.
- Targeting MVB exocytosis presents a promising host-directed therapeutic strategy against granulocytic anaplasmosis.
Related Concept Videos
Intralumenal Vesicles and Multivesicular Bodies
Intracellular Movement of Viruses and Bacteria
Lysogenic Cycle of Bacteriophages
Lytic Cycle of Bacteriophages
Viral Replication: Lytic Cycle
DNA Bacteriophages

